267 related articles for article (PubMed ID: 32253229)
1. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.
Zugazagoitia J; Gupta S; Liu Y; Fuhrman K; Gettinger S; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Aug; 26(16):4360-4368. PubMed ID: 32253229
[TBL] [Abstract][Full Text] [Related]
2. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.
Moutafi M; Martinez-Morilla S; Divakar P; Vathiotis I; Gavrielatou N; Aung TN; Yaghoobi V; Fernandez AI; Zugazagoitia J; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2022 Aug; 17(8):991-1001. PubMed ID: 35490853
[TBL] [Abstract][Full Text] [Related]
4. A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.
Muller M; Hummelink K; Hurkmans DP; Niemeijer AN; Monkhorst K; Roder J; Oliveira C; Roder H; Aerts JG; Smit EF
Clin Cancer Res; 2020 Oct; 26(19):5188-5197. PubMed ID: 32631957
[TBL] [Abstract][Full Text] [Related]
5. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
9. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H
Clin Cancer Res; 2019 May; 25(10):3026-3034. PubMed ID: 30765392
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R; Bonatti F; Mazzaschi G; Dodi A; Facchinetti F; Gelsomino F; Cinquegrani G; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Quaini F; Ardizzoni A; Tiseo M
Tumori; 2022 Feb; 108(1):47-55. PubMed ID: 34002648
[TBL] [Abstract][Full Text] [Related]
13. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
[TBL] [Abstract][Full Text] [Related]
14. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
Baglivo S; Bianconi F; Metro G; Gili A; Tofanetti FR; Bellezza G; Ricciuti B; Mandarano M; Teti V; Siggillino A; Reda MS; Chiari R; Pistola L; Sidoni A; Minotti V; Roila F; Ludovini V
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209514
[TBL] [Abstract][Full Text] [Related]
15. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
17. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
20. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]